Marinus Pharmaceuticals is a pharmaceutical company focused on the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus. The U.S Food and Drug Administration approved the use of ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder in patients two years of age and older. Co. is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The MRNS average annual return since 2014 is shown above.
The Average Annual Return on the MRNS average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MRNS average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MRNS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MRNS Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
